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A B S T R A C T
Two economically and biomedically important platyhelminth species, Fasciola hepatica (liver fluke) and
Schistosoma mansoni (blood fluke), are responsible for the neglected tropical diseases (NTDs) fasciolosis and
schistosomiasis. Due to the absence of prophylactic vaccines, these NTDs are principally managed by the single
class chemotherapies triclabendazole (F. hepatica) and praziquantel (S. mansoni). Unfortunately, liver fluke re-
sistance to triclabendazole has been widely reported and blood fluke insensitivity/resistance to praziquantel has
been observed in both laboratory settings as well as in endemic communities. Therefore, the identification of
new anthelmintics is necessary for the sustainable control of these NTDs in both animal and human populations.
Here, continuing our work with phytochemicals, we isolated ten triterpenoids from the mature bark of Abies
species and assessed their anthelmintic activities against F. hepatica and S. mansoni larval and adult lifecycle
stages. Full 1H and 13C NMR-mediated structural elucidation of the two most active triterpenoids revealed that a
tetracyclic steroid-like nucleus core and a lactone side chain are associated with the observed anthelmintic
effects. When compared to representative mammalian cell lines (MDBK and HepG2), the most potent triterpe-
noid (700015; anthelmintic EC50s range from 0.7 μM–15.6 μM) displayed anthelmintic selectivity (selectivity
indices for F. hepatica: 13 for newly excysted juveniles, 46 for immature flukes, 2 for mature flukes; selectivity
indices for S. mansoni: 14 for schistosomula, 9 for immature flukes, 4 for adult males and 3 for adult females) and
induced severe disruption of surface membranes in both liver and blood flukes. S. mansoni egg production, a
process responsible for pathology in schistosomiasis, was also severely inhibited by 700015. Together, our re-
sults describe the structural elucidation of a novel broad acting anthelmintic triterpenoid and support further
investigations developing this compound into more potent analogues for the control of both fasciolosis and
schistosomiasis.
1. Introduction
The Neglected Tropical Disease (NTD) causing flatworms Fasciola
hepatica (liver fluke responsible for fasciolosis) and Schistosoma mansoni
(blood fluke responsible for schistosomiasis) are amongst some of the
most successful parasites on the planet (Collins, 2017). Fasciolosis is
predominantly a disease of cattle and sheep, where tissue damage in-
duced by intra-definitive host parasite migration causes a loss of ∼ US
$3.2 billion per annum (Kelley et al., 2016). However, human infec-
tions are also possible, with a recent estimate indicating that ∼50
million people are currently infected worldwide (Nyindo and
Lukambagire, 2015). Morbidity associated with schistosomiasis is due
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to eggs, released by schistosome pairs into the definitive host's blood
stream, inducing T helper 2 (Th2)-mediated inflammation upon being
trapped in organs such as the liver, intestines and bladder (Pearce et al.,
1992; Warren, 1978). The long-term consequences of chronic in-
flammation leads to disease development in more than 200 million
people per annum, often killing thousands to hundreds of thousands in
endemic areas every year (Hotez and Fenwick, 2009). When con-
sidering that both fasciolosis and schistosomiasis are often found co-
endemic (Esteban et al., 2003; Yabe et al., 2008; Krauth et al., 2015),
tremendous pressure in the health care budgets and One-Health ob-
jectives can develop in countries where resources are insufficient to
meet competing financial demands. This situation is likely to be further
exacerbated as the geographical ranges of both diseases expand (Fox
et al., 2011; Holtfreter et al., 2014; Caminade et al., 2015; Hotez,
2018).
Current strategies for liver and blood fluke control are pre-
dominantly restricted to single class anthelmintics. As triclabendazole
kills all stages of Fasciola development in the definitive host (newly
excysted juveniles – NEJs, immature flukes and sexually-mature flukes),
it has been the preferred drug of choice since its introduction (Kelley
et al., 2016). However, overreliance on triclabendazole has led to
overuse and the rapid development and spread of drug resistant liver
flukes in both animals and humans (Brennan et al., 2007; Winkelhagen
et al., 2012). Without a prophylactic vaccine, the development of new
anthelmintics is urgently needed for the sustainable control of fascio-
losis. A similar situation exists for schistosomiasis, where overuse of
praziquantel threatens the rise of drug insensitive or resistant parasites
in countries engaged in wide-scale, mass drug administration (MDA)
programmes (Cupit and Cunningham, 2015). As there are also no anti-
schistosomal vaccines currently registered for use and praziquantel is
not effective against all stages of schistosome development in the de-
finitive host (Wu et al., 2011), the identification of new anthelmintic
drugs is a necessary component of sustainable schistosomiasis control
beyond 2020 (WHO, 2012). Ideally, a single compound that displays
dual activity against definitive host lifecycle stages (juveniles, im-
mature and mature flukes) of both liver and blood flukes would be
advantageous in contributing to the control of fasciolosis and schisto-
somiasis.
Towards this end, we previously have described the anthelmintic
effects of a Lycium chinense derived diterpenoid, 7-keto-sempervirol,
against both F. hepatica and S. mansoni juveniles and adults (Edwards
et al., 2015). While these effects were moderate, follow-on studies de-
tailed a total synthesis and medicinal chemistry optimisation approach
to produce thirty 7-keto-sempervirol analogues; amongst these thirty
were representative diterpenoids demonstrating increased anthelmintic
potency and selectivity (Crusco et al., 2018). Here, broadening our
search for structurally related phytochemicals, we report the anthel-
mintic activities of ten triterpenoids isolated from Abies sp. (Fir trees)
on F. hepatica and S. mansoni parasites. Preliminary structural activity
relationships (SAR) indicate that a tetracyclic steroid-like nucleus core
and a lactone side chain are associated with the observed anthelmintic
effects (e.g. reduced motility, altered phenotypes, decreased cellular
proliferation, damaged surface, diminished egg production) of the most
potent triterpenoids. These results extend the chemical space of plant-
based natural products, which display anthelmintic activity against
flukes of both veterinary and biomedical importance.
2. Materials and methods
2.1. Ethics statement
All procedures performed on mice (project license PPL 40/3700)
and sheep (project licenses PPL 40/3593, P6D805744 and PA09B4E45)
adhered to the United Kingdom Home Office Animals (Scientific
Procedures) Act of 1986 as well as the European Union Animals
Directive 2010/63/EU and were approved by Aberystwyth University's
(AU) and Ridgeway Research Limited's (RRL) Animal Welfare and
Ethical Review Bodies (AWERB).
2.2. Isolation of triterpenoids from abies species
A total of ten triterpenoid compounds were isolated from di-
chloromethane (DCM) extracts of the mature bark of Abies species
grown in Wales (UK) by normal phase and reverse phase chromato-
graphic systems. Photodiode array and mass spectrophotometry de-
tection to monitor peak separations were also applied during the iso-
lation process. For specific isolation of the most active compound
700015, mature branches (600 g) of Abies procera (the Noble Fir) were
collected in January by Forest Research (now Natural Resources Wales)
at Cefn Gethiniog, Talybont-on-Usk, Brecon, Powys (reference N10122)
and given PhytoQuest code IG289; this starting material was used to
purify 160 mg of pure (> 95%) compound. Here, the DCM extraction of
the freeze-dried ground material was conducted in a Soxhlett overnight
and the extract cleaned using Diaion HP20 resin. Normal phase flash
chromatography using Dionex cartridges and heptane:ethyl acetate
(70:30) was monitored at 210 nm and the fraction further separated
using preparative high performance liquid chromatography (HPLC,
NovaPak08 radial compression) with water: acetonitrile: acetoni-
trile + 0.1% TFA (26:65:10) giving the pure compound. The second
most active compound, 700234, was purified by the same method from
1 kg of mature bark of Abies grandis (the Grand Fir; collected in January
from the same location) supplied by Natural Resources Wales
(N10127), yielding 750mg of pure (> 95%) compound. A reference
sample was given the PhytoQuest code IG294.
Compound 700015 gave a distinctive mass spectrum (EI, 70 eV)
with major ion 325 atomic mass units (Waters Integrity) while 700234
had distinctive ions at 295 (100%) and 313 (50%) atomic mass units.
The UV spectra were end absorbing (200 nm) and not informative.
Using an analytical HPLC system, the retention time was 8.4min for
700015 and 9.5min for 700234. The analytical method used a C8 HPLC
column (50mm×4.6mm id x 3.5 μm, Waters) with a flow rate of
1.5 mL/min and a linear gradient that started at 90% water and 10%
acetonitrile (containing 0.01% trifluoroacetic acid), rising to 100%
acetonitrile over 6min, which was held for a further 6min. Structural
elucidation was conducted using NMR spectroscopy on a 500MHz
Bruker Avance instrument. Mass spectrometry was performed on an
Orbitrap Fusion Thermo Scientific with a Dionex UltiMate 3000 UHPLC
system.
2.3. Structural elucidation of triterpenoid 700015
Colourless oil, structural elucidation involved two steps. Purified
700015 was characterised by high resolution mass spectrometry
(HRMS) together with 1H, 13C and two-dimensional Nuclear Magnetic
Resonance (NMR) spectroscopy. Peak lists for 1H NMR (500MHz,
CDCl3) δ/ppm: 6.83 (1H, broad s, 23), 5.43 (1H, m, 7), 2.41 (2H, m, 2)
2.00 (1H, m, 9), 1.87 (1H, m, 21) 1.86 (1H, m, 19), 1.81 (2H, m, 16),
1.75 (2H, m, 6), 1.68 (3H, s, 26), 1.65 (1H, m, 1), 1.61(1H, m, 11), 1.55
(1H, m, 1), 1.53 (1H, m, 11), 1.43 (1H, m, 21), 1.38 (2H, m, 15), 1.35
(1H, m, 5), 1.25 (3H, m, 12 and 17), 0.93 (6H, s, 29 and 30), 0.82 (6H,
s, 20 and 27), 0.78 (3H, s, 18), 0.58 (3H, s, 28). Peak lists for 13C NMR
(126MHz, CDCl3) δ/ppm: 218.4 (C=O, 3), 171.4 (C=O, 25), 149.0 (C,
8), 148.9 (CH, 23), 131.8 (C, 24), 106.1 (C, 22), 53.9 (CH, 5), 52.7 (CH,
17), 52.7 (C, 14), 47.3 (C, 4), 45.9 (CH, 9), 44.0 (CH2, 21), 43.7 (C, 13),
36.2 (CH2, 15), 35.7 (C, 10), 35.7 (CH2, 1), 34.8 (CH2, 2), 33.3 (CH,
19), 33.3 (CH2, 12), 29.1 (CH2, 16), 28.4 (CH3, 30), 27.7 (CH3, 20),
23.5 (CH2, 11), 23.5 (CH3, 18), 23.4 (CH3, 27), 23.3 (CH2, 6), 22.7
(CH3, 29), 21.7 (CH3, 28) 10.3 (CH3, 26). HRMS-ESI m/z: [M + H]+
calculated for C30H45O4 is 469.3318 and experimentally determined to
be 469.3317. According to SciFinder (https://www.cas.org/products/
scifinder) searches, 700015 has been previously isolated from Abies
holophylla (Kim et al., 2018) and Abies sibirica (Korolev et al., 2003;
H.L. Whiteland et al. IJP: Drugs and Drug Resistance 8 (2018) 465–474
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Handa et al., 2013).
2.4. Structural elucidation of triterpenoid 700234
Colourless oil, structural elucidation involved two steps. Purified
700234 was characterised by HRMS and two-dimensional (1H, 13C)
NMR spectroscopy. Peak lists for 1H NMR (500MHz, MeOD) δ/ppm:
6.91 (1H, m, 23), 5.68 (1H, m, 11), 5.55 (1H, m, 6), 3.42 (2H, m, 3 and
16), 2.29 (1H, m, 12), 2.09 (1H, m, 7), 2.08 (1H, m, 12), 2.07 (1H, m,
1), 2.04 (1H, m, 19), 1.94 (H, m, 17), 1.93 (1H, m, 21), 1.91 (1H, m,
15), 1.89 (3H, d, J=7.5 Hz, 26), 1.87 (1H, m, 7), 1.86 (1H, m, 21),
1.82 (1H, m, 2), 1.56 (2H, m, 2 and 15), 1.36(1H, m, 1), 1.11 (3H, s,
18), 1.02 (3H, s, 29), 1.01 (3H, s, 30), 0.98 (6H, s, 27 and 28), 0.92 (3H,
d, overlayed, 20). Peak lists for 13C NMR (126MHz, MeOD) δ/ppm:
174.6 (C=O, 25), 157.8 (C, 5), 149.9 (CH, 23), 147.9 (C, 9), 132.3 (C,
24), 124.9 (CH, 6), 120.9 (CH, 11), 109.4 (C, 22), 78.2 (CH, 16), 75.2
(CH, 3), 51.7 (C, 4), 50.6 (C, 14), 49.9 (C, 13), 48.8 (CH2, 15), 39.8
(CH2, 21), 39.7 (C, 10), 37.2 (CH, 17), 36.9 (CH2, 7), 36.4 (CH, 8), 35.1
(CH2, 1), 30.3 (CH, 19), 27.5 (CH3, 30), 27.4 (CH3, 18), 24.9 (CH2, 2),
24.7 (CH3, 29), 19.8 (CH3, 27), 19.1 (CH3, 28), 18.9 (CH3, 20), 10.3
(CH3, 26). HRMS-ESI m/z: [M + H]+ calculated for C30H43O4 is
467.3161 and experimentally determined to be 467.3169. According to
searches in PubChem (https://pubchem.ncbi.nlm.nih.gov/search/) and
SciFinder (https://www.cas.org/products/scifinder), 700234 re-
presents a novel chemical entity.
2.5. Compound storage and handling
All ten triterpenoids were solubilised in DMSO (Fisher Scientific,
UK) to a stock concentration of 10mM and stored at −20 °C until re-
quired. For all fluke screens, compounds were further diluted to a
working concentration of 1.6mM in DMSO. Positive controls for S.
mansoni screens included praziquantel (Sigma-Aldrich, UK) and aur-
anofin (Sigma-Aldrich, UK), which were also diluted in DMSO to a stock
concentration of 10mM and working concentration of 1.6 mM. A po-
sitive control for F. hepatica screens included triclabendazole (Sigma-
Aldrich, UK), which was diluted in DMSO to a working concentration of
10mM.
2.6. Screening of F. hepatica newly excysted juveniles (NEJs)
Metacercariae of a F. hepatica Italian strain were supplied by RRL
and an excystment was performed as previously described (Crusco
et al., 2018). After excystment, NEJs were distributed into a 24 well
tissue culture plate at a density of 25 parasites per well containing 1mL
of fresh RPMI 1640 media (Gibco, Paisley, UK) supplemented with 1%
v/v Foetal Calf Serum (Gibco, Paisley, UK) and 1X v/v antibiotic/an-
timycotic solution (Sigma-Aldrich, UK). All ten triterpenoids were
added to respective wells and NEJ/compound co-cultures were in-
cubated at 37 °C in an atmosphere containing 5% CO2 for 72 h at a final
concentration of 10 μM; phenotype and motility was independently
scored using the scoring matrix as described previously (Edwards et al.,
2015). Controls included NEJs cultured in 0.1% DMSO (negative) or
10 μM Triclabendazole (in 0.1% DMSO; positive). A dose response ti-
tration of 700015 involved the co-cultivation (as described above) of 25
NEJs per well containing final triterpenoid concentrations of 10 μM,
5 μM, 2.5 μM, 1.25 μM and 0.625 μM (all in 0.1% DMSO).
2.7. Screening of immature and adult F. hepatica liver flukes
Lambs (Texel Mule X, 6 months old) were orally infected with 200
F. hepatica (Italian strain) metacercariae and, four and 8wk later, im-
mature and mature liver fluke were obtained and prepared as pre-
viously described (Crusco et al., 2018). Immature flukes (n=3/con-
dition) were transferred to 6-well plates (Thermo Scientific, Denmark)
containing 3mL of RPMI 1640 media (Gibco, Paisley, UK)
supplemented with 2.5% HEPES (Sigma-Aldrich), 1X v/v antibiotic/
antimycotic solution (Gibco, Paisley, UK) and 1% Foetal Bovine Serum
(Gibco, Paisley, UK). Immature parasites were co-cultured at 37 °C in an
atmosphere containing 5% CO2 with 700015 at 40 μM, 13.3 μM and
4.4 μM for 72 h; compound-induced motility defects were scored as
previously described (Crusco et al., 2018).
Adult liver flukes (n=3/condition) were transferred to 15mL
falcon tubes containing 6mL of the same medium used for cultivating
immature flukes and co-cultured at 37 °C in an atmosphere containing
5% CO2 with 700015 at 40 μM, 13.3 μM and 4.4 μM for 72 h. Every
24 h, 2mL of fresh media and 700015 was added to each of the cul-
tures; compound-induced motility defects were again scored according
to Crusco et al. (2018). In both 4 wk old and 8wk old liver fluke
screens, control parasites included those treated with 0.4% DMSO
(negative) or 40 μM Triclabendazole (in 0.4% DMSO, positive).
2.8. Screening of S. mansoni schistosomula
Biomphalaria glabrata (NMRI strain) snails infected with S. mansoni
(Puerto Rican strain) were shed for 2 h under light conditions at 26 °C.
Cercariae were collected, mechanically transformed into schistosomula
(Colley and Wikel, 1974) and subsequently prepared for high
throughput screening (HTS) on the Roboworm platform as previously
described (Crusco et al., 2018; Nur et al., 2017). Schistosomula were
added to each well containing triterpenoids (10 μM in 0.625% DMSO)
at a density of 120 parasites per well. Parasites were cultured at 37 °C in
an atmosphere containing 5% CO2 for 72 h with phenotype and motility
of each parasite quantified using a previously described image analysis
model (Paveley et al., 2012). Control treatments included schistoso-
mula cultured in the presence of praziquantel (10 μM in 0.625%
DMSO), auranofin (10 μM in 0.625% DMSO) and DMSO (0.625%). A
dose response titration of 700015 involved the co-cultivation (as de-
scribed above) of 120 schistosomula per well containing final tri-
terpenoid concentrations of 10 μM, 5 μM, 2.5 μM, 1.25 μM and
0.625 μM (all in 0.625% DMSO).
2.9. Screening of juvenile S. mansoni blood flukes (3-week worms)
Juvenile S. mansoni adult parasites were recovered from MF-1 mice
(Harlan, UK) that were infected percutaneously three weeks earlier
with 4000 cercariae. Worms were transferred into 50mL falcon tubes
and centrifuged at 300×g for 2min. This pellet was collected, washed
in phenol-red free DMEM and subjected to repeat centrifugation. This
procedure was repeated a further two times, where on the final wash,
the parasites were pelleted by gravity. This final, washed pellet was
collected and placed in culture media (DMEM media (Gibco, Paisley,
UK) supplemented with 10% v/v Hepes (Sigma-Aldrich, Gillingham,
UK), 10% v/v Foetal Bovine Serum (Gibco, Paisley, UK), 0.7% v/v
200mM L-Glutamine (Gibco, Paisley, UK) and 1X v/v penicillin-strep-
tomycin (Gibco, Paisley, UK).
A total of 6–19 juvenile worms were transferred to each well of a 96
well plate containing a final volume of 200 μL of media containing
700015 at the following concentrations: 15 μM, 7.5 μM, 3.75 μM and
1.83 μM (in 1.25% DMSO). This was repeated three times (n=3).
Parasites were cultured at 37 °C in an atmosphere containing 5% CO2
for 72 h at which time worm motility was scored between 0 and 4:
0=dead, 1=movement of the suckers only and slight contraction of
the body, 2=movement at the anterior and posterior regions only,
3= full body movement but sluggish and 4= normal movement.
2.10. Screening of adult S. mansoni blood flukes (7-week worms)
Adult S. mansoni parasites were recovered by hepatic portal vein
perfusion from MF-1 mice (Harlan, UK) that were percutaneously in-
fected seven weeks earlier with 200 cercariae. Three adult worm pairs
per well, in duplicate, were transferred into 48 well plates (Fisher
H.L. Whiteland et al. IJP: Drugs and Drug Resistance 8 (2018) 465–474
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Scientific, Loughborough, UK) and cultured at 37 °C in an atmosphere
containing 5% CO2 in DMEM media (Gibco, Paisley, UK) containing
10% v/v HEPES, 10% v/v Foetal Bovine Serum, 0.7% v/v 200mM L-
Glutamine and 1X penicillin-streptomycin (Gibco, Paisley, UK). A total
of 3 biological repeats were conducted giving a total of 18 males and 18
females dosed per treatment. Worms were dosed with test compounds
at 20 μM, 10 μM, 5 μM, 2.5 μM, 1.25 μM and 0.625 μM (in 1.25%
DMSO) for 72 h. Adult worms were scored manually at 72 h using the
WHO-TDR metric scoring system as described previously (Ramirez
et al., 2007). At 72 h, the medium from each well was collected, cen-
trifuged at 1000 rpm for 2min, supernatant removed and remaining
egg pellet re-suspended in 10% v/v formalin. Normal shaped eggs that
were oval and contained a fully-formed lateral spine were subsequently
counted.
2.11. Preparation of adult F. hepatica and S. mansoni worms for scanning
electron microscopy (SEM)
Adult liver and blood flukes were cultivated (as described above) in
sub lethal concentrations of 700015 (F. hepatica – 13.3 μM; S. mansoni –
10 μM) for 72 h. Afterwards, flukes were prepared for SEM as pre-
viously described (Crusco et al., 2018).
2.12. Quantification of EdU positive cells in adult S. mansoni worms
Adult S. mansoni worms were cultured (as described above) for 72 h
in a sub lethal concentration of 700015 (10 μM). After 72 h, a 1 μL
aliquot of 10mM EdU was added to the culture media and incubated for
a further 24 h. Worms were subsequently collected and fixed as de-
scribed previously (Collins et al., 2013; Geyer et al., 2018). Anterior
regions of both sexes were imaged on a Leica TCS SP5II confocal mi-
croscope using a 40× lens. A total of 150 Z-stacks were obtained for
each individual worm (n= 10 for males, n= 5–7 females). EdU posi-
tive cells were quantified using Imaris v8.2 (BitPlane, UK) by analysing
the fluorescent intensity of DAPI and EdU expressed as a total volume
(μm3) occupied by each fluorophore.
2.13. MTT assay on HepG2 and madin darby bovine kidney (MDBK) cells
Overt cytotoxicity of 700015 was assessed on both human HepG2
and bovine MDBK (NBL-1) cells as described previously (Crusco et al.,
2018). Briefly, 2× 104 cells/well (HepG2) or 7.5×103 cells/well
(MDBK) were seeded in black walled 96-well microtiter plates (Fisher
Scientific, Loughborough, UK) and incubated for 24 h at 37 °C in a hu-
midified atmosphere containing 5% CO2. To each well, 700015 was
subsequently added to obtain final concentrations (in 1% DMSO) of
100 μM, 75 μM, 50 μM, 25 μM, 10 μM and 5 μM (HepG2 cells) or
100 μM, 75 μM, 50 μM, 20 μM, 10 μM and 5 μM (MDBK cells); negative
(1% DMSO) and positive (1% v/v Triton X-100) control wells were
included for both cell types. Following a further incubation for 24 h, the
MTT assay was performed as previously described (Nur et al., 2017;
Crusco et al., 2018).
2.14. Statistics
All Statistical analyses were conducted using GraphPad Prism 7
software. To determine significant differences amongst population
means, a Kruskal-Wallis ANOVA followed by Dunn's multiple compar-
isons test was used.
3. Results and discussion
Investment in drug discovery research for NTDs is dis-
proportionately low when compared to the impact that these diseases
have on both animal and human lives. Therefore, pragmatic approaches
for identifying new compounds to be used in de novo NTD drug
discovery programmes have been developed and include drug re-
purposing/repositioning, drug rescuing, target repositioning and lead
repurposing (Renslo and McKerrow, 2006; Panic et al., 2014; Klug
et al., 2016; Gouveia et al., 2018). These approaches, often aided by
public-private collaborations (Woods and Knauer, 2010; Ramamoorthi
et al., 2014), can dramatically save time and money as the systematic
optimisation of candidate molecules are minimised at this point in the
pipeline.
In this regard, terpene/terpenoid phytochemicals have previously
been explored and repurposed for their synergistic anti-parasitic cap-
abilities; a well-known example is artemisinin, an endo-peroxide con-
taining sesquiterpenoid lactone derived from Artemisia annua.
Originally reported to inhibit Plasmodium proliferation (Su and Miller,
2015), artemisinin has subsequently been shown to affect other para-
sitic protozoan and helminth species (Loo et al., 2017; Lam et al.,
2018). Of interest to the current study, in vitro cultivated F. hepatica and
S. mansoni are both susceptible to artemisinin-based chemotherapies
(Keiser and Utzinger, 2007). While the clinical progression of this
particular sesquiterpenoid for both fasciolosis and schistosomiasis
control has slowed (Hien et al., 2008; Utzinger et al., 2010), the search
for other related di- or triterpenoids with anthelmintic activity con-
tinues (Kayser et al., 2003; Acevedo et al., 2017). Here, expanding on
our previous investigations (Edwards et al., 2015; Crusco et al., 2018),
we investigated the dual (F. hepatica and S. mansoni) anthelmintic ac-
tivity of ten triterpenoids isolated from the bark of an indigenous
coniferous species from Wales, United Kingdom (A. procera and A.
grandis).
Using a numerical matrix to quantify both phenotype and motility,
the ten isolated triterpenoids (Supplementary Figure 1) were first tested
(at 10 μM) for activity against the NEJ stage of F. hepatica (Fig. 1).
Separate wells containing NEJs co-cultivated with triclabendazole
(10 μM) or DMSO were also included as controls. Most of the triterpe-
noids tested did not significantly affect NEJ phenotype (60%, Fig. 1A)
or motility (80%, Fig. 1B) after 72 h of co-culture. However, amongst
the four compounds that significantly affected NEJ phenotype (700015,
700234, 700638 and 700657), two (700015 and 700234) also sig-
nificantly affected NEJ motility. When compared to the positive control
triclabendazole (10 μM), 700015 (> 700234) was equally potent in
affecting both NEJ phenotypic and motility metrics. In a second
bioassay using an automated high throughput anthelmintic platform
(Nur et al., 2017), these same four triterpenoids (at 10 μM) were also
found to affect both S. mansoni schistosomula motility and phenotypic
measures (Fig. 2, Hit zone). Amongst these four, 700015 and 700234,
again, were the most effective (700015 > 700234 due to its position
within the hit zone being closer to the origin) with anti-schistosomula
activity after 72 h of co-culture being greater than that measured for
praziquantel (10 μM). These results prompted us to investigate struc-
tural activity relationships (SAR) of the ten triterpenoids to provide an
explanation underlying their differential effects on both F. hepatica and
S. mansoni larval developmental stages (Fig. 3 and Supplementary
Figure 1).
Amongst the ten triterpenoids tested (Supplementary Figure 1), five
of them are considered pentacyclic triterpenoid saponins (700496,
700500, 700501, 700502, 700503). Interestingly, none of these five
showed significant activity against either F. hepatica NEJs or S. mansoni
schistosomula at the concentration tested (Table 1). However, when the
glycoside moieties were absent or replaced (e.g. 700638), but the same
pentacyclic structure of the saponin aglycone remained, the activity
increased. We concluded from this preliminary SAR analysis that the
presence of glycoside moieties decreased anthelmintic activity; this
triterpenoid modification may be associated with decreased lipophilia
(negative LogP values for the glycoside containing pentacyclic tri-
terpenoids 700496, 700500, 700501, 700502 and 700503 are found
when compared to the other triterpenoids in this study, Supplementary
Figure 1) and the inability to cross heptalaminate membranes of both
liver and blood flukes. However, as saponins are known to be
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hydrolysed when ingested (Francis et al., 2002), the in vivo anthelmintic
characteristics could be quite different to those obtained from in vitro
studies.
More interesting is the structural comparison of the most active
triterpenoids (700015 and 700234) to the less active triterpenoid
(700657) and finally to the completely inactive triterpenoid 700019; all
four compounds share a tetracyclic steroid-like nucleus (Fig. 3A and
Supplementary Figure 1). While the substitution of a keto or hydroxy
group on ring A (considering the classic triterpenoid lettering system
(Moss, 1989)) does not affect anthelmintic activity (700234 and
700019 have a hydroxy group, while 700015 and 700657 contain a
keto group), the lactone side chain of ring D could potentially have a
major role (Fig. 3B). Indeed, both 700015 and 700234 share this fea-
ture (Fig. 3A) whereas 700019 has lost it (i.e. lactone ring has opened).
Moreover, the greater activity of 700015 over 700234 could be ex-
plained by the flexibility of the lactone ring (i.e. 700015 has a more
flexible lactone ring when compared to 7000234). The screening of
additional triterpenoids with similar features could potentially confirm
these preliminary SAR observations and provide important indications
on how the anthelmintic activity of these molecules can be increased.
Nevertheless, as 700015 displayed the greatest dual anthelmintic ac-
tivity on NEJs and schistosomula (at 10 μM), we subsequently quanti-
fied the potency (dose response titrations) and selectivity (bovine and
human cell line cytotoxicity) of this triterpenoid.
Dose response titrations of 700015 revealed similar potencies on
both F. hepatica NEJs and S. mansoni schistosomula motility and phe-
notype metrics after 72 h of co-culture (Fig. 4). Here, EC50 values for F.
hepatica NEJs were 2.4 μM (for both phenotype and motility) (Figs. 4A)
and 1.9 μM (motility) to 2.6 μM (phenotype) for S. mansoni schistoso-
mula (Fig. 4B). As these anthelmintic potency values exceeded our
previous results obtained from related diterpenoids (Edwards et al.,
2015; Crusco et al., 2018), we extended dose response titrations of
700015 against immature and mature fluke developmental stages of
both species (Fig. 5).
In terms of F. hepatica, all concentrations of 700015 tested (40 μM,
13.3 μM and 4.4. μM) considerably affected the motility of immature
(4 wk old) parasites (Fig. 5A); this triterpenoid-induced effect
(EC50= 0.7 μM) was equivalent to that seen for immature flukes co-
cultured with triclabendazole (40 μM). Due to the limitations in im-
mature fluke numbers, we were unable to titrate 700015 further and,
thus, this EC50 is an estimate only. Adult (8 wk old) liver flukes were
only significantly affected by higher concentrations of 700015 (40 μM).
While this triterpenoid-induced effect (EC50= 15.6 μM) was equivalent
to that seen in adult flukes co-cultivated with triclabendazole (40 μM), a
steep drop in activity was seen at 700015 concentrations below
13.3 μM. Nevertheless, as triclabendazole represents the only liver flu-
kicide on the market with activity against NEJs, immature flukes and
adults (Kelley et al., 2016), the results of these in vitro studies suggest
that 700015 contains an important criterion for fasciolosis control
considerations.
Regarding S. mansoni, 700015 significantly affected the motility of
immature (3 wk old) parasites at all concentrations tested except
1.83 μM (Fig. 5C). While some individual variability was observed at
Fig. 1. Of the ten triterpenoids isolated from Abies sp., two (700015 and
700234) had significant activity against Fasciola hepatica newly excysted
juveniles (NEJs). F. hepatica NEJs (25 per well) were incubated with ten tri-
terpenoids at a concentration of 10 μM (in 0.1% DMSO) and cultured for 72 h at
37 °C in an atmosphere containing 5% CO2. Control wells (25 NEJs per well)
included those containing 0.1% DMSO (negative) or 10 μM Triclabendazole
(0.1% DMSO, positive). At 72 h, all NEJs were scored for phenotype (A) and
motility (B) metrics as previously described (Edwards et al., 2015). *p = 0.05,
**p = 0.01, ***p=0.001.
Fig. 2. Four triterpenoids, including 700015 and 700234, negatively affect
Schistosoma mansoni schistosomula phenotype and motility metrics.
Mechanically transformed schistosomula (120 per well) were cultivated in the
presence of triterpenoids (10 μM in 0.625% DMSO) for 72 h at 37 °C in an at-
mosphere containing 5% CO2. Control wells included schistosomula cultivated
in DMSO (0.625%, negative), auranofin (in 0.625% DMSO, positive) and pra-
ziquantel (in 0.625% DMSO, positive). At 72 h, all schistosomula were scored
for phenotype and motility as previously described (Paveley et al., 2012).
Compounds were considered a hit (within the hit zone) when schistosomula
phenotype fell below −0.15 and schistosomula motility fell below −0.35. The
Z' values for this screen was 0.4 for motility and 0.5 for phenotype.
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each compound concentration, an EC50 of 3.4 μM was calculated for
these mixed-sex parasite populations. Extending these assays to adult
schistosome (7 wk old) mixed-sex cultures revealed a greater triterpe-
noid-mediated effect on male (EC50= 7.4 μM) compared to female
(EC50= 10.3 μM) parasites. Although this gender biased (male >
female) effect has been observed before for other (di- and sesqui-)
terpenes/terpenoids (Edwards et al., 2015; de Oliveira et al., 2017), this
is not always seen (de Moraes et al., 2014) and is most likely related to
structural differences amongst this diverse class of compounds (de
Moraes, 2015; Mafud et al., 2016). Interestingly, egg production was
also significantly inhibited in mixed-sex adult worm cultures even at
concentrations of 700015 below the EC50s (5 μM - 2.5 μM) calculated
for this lifecycle stage (Fig. 5E). This decrease in egg production was
directly correlated with a loss of male/female pairing. In contrast to the
DMSO controls, where between 10 and 12 schistosome pairs (starting
from n=18 pairs) remained coupled after 72 h of culture, only 1–4
schistosome pairs (starting from n=18 pairs) remained together when
cultivated in the presence of 700015 (regardless of concentration).
These results suggested that 700015 induced a stress response in adult
Fig. 3. A lactone ring is associated with the dual anthelmintic activity of the two most effective triterpenoids. (A) The structural elucidation of triterpenoids
700015 and 700234 revealed a tetracyclic steroid-like nucleus core, a keto- (700015) or hydroxyl- (700234) group and a conserved lactone ring. ‘A, B, C, D’ represent
the classic lettering system for steroids (Moss, 1989). Carbon numbering is derived from the 13C NMR structural elucidation of each triterpenoid. (B) Representative
images of F. hepatica NEJs co-cultivated with DMSO (0.1%, negative control), TCBZ (10 μM in 0.1% DMSO, positive control), 700015 (10 μM in 0.1% DMSO) and
700234 (10 μM in 0.1% DMSO) obtained by bright field microscopy (20× objective) compared to representative images of S. mansoni schistosomula co-cultivated
with DMSO (0.625%, negative control), PZQ (10 μM in 0.625% DMSO, positive control), 700015 (10 μM in 0.625% DMSO) and 700234 (10 μM in 0.625% DMSO)
obtained by the high content imaging platform (10× objective). All parasite images were acquired at 72 h post parasite/compound co-cultivation.
Table 1
Triterpenoid activity against F. hepatica newly excysted juveniles (NEJs) and S.
mansoni schistosomula.
Triterpenoid F. hepatica S.mansoni
Phenotype Motility Phenotype Motility
700015 ✓ ✓ ✓ ✓
700019 – – – –
700234 ✓ ✓ ✓ ✓
700496 – – – –
700500 – – – –
700501 – – – –
700502 – – – –
700503 – – – –
700638 ✓ – ✓ ✓
700657 – – ✓ ✓
Parasites were incubated for 72 h at 37 °C in a humidified atmosphere in ap-
propriate media containing 10 μM triterpenoid and scored according to
Materials and Methods. Triterpenoids not affecting (−) or affecting (✓) para-
site phenotype and motility metrics are indicated.
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schistosomes, which significantly impacted upon pairing and oviposi-
tion. While the molecular nature of this 700015-mediated stress re-
sponse is currently unknown, it appears to also affect somatic stem cell
(neoblast) proliferation (males > females) (Fig. 5F). As stem cell pro-
liferation/differentiation and egg production are critical processes re-
sponsible for lifecycle transmission and immunopathology development
(Pearce et al., 1992; Collins et al., 2013; Wang et al., 2018), these
findings could hold relevance to schistosomiasis control. Due to lim-
itations in parasite material, the effect of 700015 on F. hepatica stem
cell proliferation and egg production was not examined in this study.
Previous studies have demonstrated that the anthelmintic activity
observed for mono-, di- and sesqui-terpenes/terpenoids is correlated to
surface damage of both F. hepatica and S. mansoni (Keiser and Utzinger,
2007; Keiser and Morson, 2008; de Moraes et al., 2013; Moraes et al.,
2013; Edwards et al., 2015; de Oliveira et al., 2017; Crusco et al.,
2018). Therefore, we next investigated whether tegumental surface
membranes of both liver and blood flukes were negatively affected by
sub-lethal concentrations (13.3 μM for F. hepatica adults, 10 μM for S.
mansoni adults) of 700015 (Fig. 6). After 72 h of co-culture, clear al-
terations in the normal architecture of tegumental surfaces were
observed in both species. For example, 700015 induced erosion of
spines surrounding the acetabulum of liver flukes and mediated wide-
spread tegumental dehydration/invagination (Fig. 6A). Small mem-
branous blebs of the surface were also more apparent in 700015 treated
liver flukes when compared to controls (DMSO). In blood flukes,
700015 led to severe disruption of the tegumental barrier with nu-
merous membranous blebs and abrasions observed throughout the
length of both male (5 out of 7 examined) and female (5 out of 6 ex-
amined) worms (Fig. 6B). As schistosome egg production is significantly
affected at this triterpenoid concentration (Fig. 5E), it would appear
that an intact tegumental barrier is partially responsible for main-
taining this key parasitological trait.
The mechanism of action (MOA) behind these commonly observed
anthelmintic phenotypes (i.e. surface membrane defects) is currently
unknown, but extrapolating findings from other systems implicates
membrane disruption, lipase inhibition, mitochondrial dysfunction and
cholesterol homeostasis alterations (Slamenova et al., 2004; Handa
et al., 2013; Kathuria et al., 2014; Kuzu et al., 2014) as possibilities.
While this study's scope was not designed to explore MOA in detail, we
sought to indirectly explore this area by assessing the general
Fig. 4. Dose response titration of the most active triterpenoid on Fasciola hepatica newly excysted juveniles (NEJs) and Schistosoma mansoni schistoso-
mula. (A) F. hepatica NEJs (25 per well) were incubated with 700015 at concentrations of 10 μM, 5 μM, 2.5 μM, 1.25 μM and 0.625 μM (in 0.1% DMSO) and cultured
for 72 h at 37 °C in an atmosphere containing 5% CO2. A negative control well (25 NEJs per well) was included (0.1% DMSO) and is represented by −1.0 on the
graphs. At 72 h, all NEJs were scored for phenotype and motility metrics. (B)Mechanically transformed schistosomula (120 per well) were cultivated in the presence
of 700015 (10 μM, 5 μM, 2.5 μM, 1.25 μM and 0.625 μM in 0.625% DMSO) for 72 h at 37 °C in an atmosphere containing 5% CO2. A control well included schis-
tosomula cultivated in DMSO (0.625%, negative; represented by −1.0 on the graphs). At 72 h, all schistosomula were scored for phenotype and motility. The Z'
values for this screen was 0.4 for motility and 0.5 for phenotype.
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Fig. 5. Immature and adult stages of Fasciola hepatica and Schistosoma mansoni are affected by the most active triterpenoid 700015. (A) Immature F.
hepatica parasites (4 weeks post infection; n=3) were cultured in the presence of a decreasing concentration of 700015 (40 μM, 13.3 μM and 4.4 μM in 0.4% DMSO)
and motility scored at 72 h. Control parasites (n= 3 per condition) included those co-cultivated in RPMI only, RPMI containing 0.4% DMSO (negative) and TCBZ
(40 μM in 0.4% DMSO, positive). (B) Adult F. hepatica parasites (8 weeks post infection; n= 3) were also cultured in the same 700015 titrations and motility metrics
scored at 72 h and compared to control parasites. (C) Juvenile S. mansoni worms (3 weeks post infection; total number of parasites tested per condition= 26 - 33)
were cultured in a titration of 700015 (20 μM, 15 μM, 7.5 μM, 3.75 μM and 1.88 μM in 1.25% DMSO) and motility scored at 72 h. Control parasites (n= 78) included
those co-cultivated in the presence of 1.25% DMSO. (D) Adult S. mansoni worm pairs (7 weeks post infection; n= 18) were cultured in a decreasing dose of 700015
(20 μM, 10 μM, 5 μM, 2.5 μM, 1.25 μM and 0.625 μM in 0.2% DMSO) and motility scored at 72 h. (E) Media from adult S. mansoni worm cultures were collected at
72 h and counted for the presence of eggs. (F) Adult S. mansoni worm pairs were co-cultivated with a sub-lethal concentration of 700015 (10 μM) for 72 h and EdU
positive cells quantified from the anterior (to ovaries and testes) region of each gender (male = 9–10 individuals; female = 5–7 individuals). In all panels, *p= 0.05,
**p = 0.01, ***p=0.001.
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cytotoxicity of 700015 on two representative mammalian cell lines,
MDBK and HepG2 (Supplementary Figure 2). Using an MTT assay to
detect mitochondrial NAD(P)H-dependent oxidoreductase activity,
CC50 values calculated for 700015 were found to be similar for both
bovine (CC50= 33 μM) and human (CC50= 32 μM) cell lines; these
data indicated a low to moderate degree of general cytotoxicity for this
triterpenoid. These findings are similar to those published previously,
where moderate 700015 - mediated cytotoxicities on SK-OV-3 (human
ovary malignant ascites; CC50 > 10 μM), HCT15 (human colon ade-
nocarcinoma; CC50 > 10 μM), A549 (human non-small-cell lung ade-
nocarcinoma; CC50= 9.4 μM) and SK-MEL-2 (human skin melanoma;
CC50= 4.1 μM) cell lines were demonstrated (Kim et al., 2018).
Nevertheless, when compared to the effect that 700015 had on the
stages of helminth development studied herein for both species, the
selectivity indices (SI = CC50/IC50) of this triterpenoid ranged between
3 and 46; the exception being adult liver fluke where the SI was 2
(Table 2). These values demonstrated that 700015 exhibited more se-
lective activity against the parasitic flukes than the mammalian cell
lines. Indeed, these SI values, generally, exceeded those obtained for
related diterpenoids currently under study in our laboratory (Edwards
et al., 2015; Crusco et al., 2018). Collectively, a window of selectivity
between surrogate mammalian cell lines and flukes (in some cases,
moderate to high) was established for 700015, suggesting that medic-
inal chemistry optimisation of this triterpenoid could lead to the gen-
eration of more specific anthelmintic analogues.
In summary, a novel phytochemical (700015) was isolated from the
bark of A. procera and chemically defined as a triterpenoid containing a
tetracyclic steroid-like nucleus and lactone side chain. These core
structures were associated with moderately potent and selective an-
thelmintic activities against larval, immature and mature lifecycle
stages of both F. hepatica and S. mansoni flatworm parasites. Further
investigations of this novel triterpenoid for the control of both fascio-
losis and schistosomiasis are warranted.
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Fig. 6. The triterpenoid 700015 induces surface damage to both her-
maphroditic F. hepatica and dioecious S. mansoni adults. (A) Adult F. he-
patica (n= 3) were cultured for 72 h in media containing a sub-lethal con-
centration (13.3 μM in 0.13% DMSO) of 700015. When compared to control
parasites (0.13% DMSO; n= 3) at 72 h, 700015 induced spine erosion and ir-
regular invaginations of the surface tegumental membranes surrounding the
acetabulum. (B) Adult S. mansoni worm pairs (males and females; n=7 pairs)
were cultured for 72 h in a sub-lethal concentration (10 μM in 1.25% DMSO) of
700015. When compared to control parasites (1.25% DMSO; n=7 pairs),
700015 led to tegumental surface disruption and membrane blebbing in 5/7
males and 5/6 females (1 female did not survive the SEM processing).
Table 2
Summary of anthelmintic activities and selectivity indices of 700015.
Biological material and parameters
assessed
EC50 (parasites)
and CC50 (cells)
values
Selectivity
Indexb
F. hepatica Newly excysted
juvenilles
Motility 2.4 μM 13.3
Phenotype 2.4 μM 13.3
Immature Motility 0.7 μMa 45.7
Adult Motility 15.6 μM 2
S. mansoni Schistosomula Motility 1.9 μM 16.6
Phenotype 2.6 μM 12.2
Immature Motility 3.4 μM 9.4
Adult Male Motility 7.4 μM 4.3
Adult Female Motility 10.3 μM 3.1
Cell Lines MDBK Viability 33 μM
HepG2 Viability 32 μM
a The EC50 of 700015 on F. hepatica juveniles is an estimate only.
b Selectivity indices for F. hepatica lifecycle stages were calculated from
MDBK CC50 values; selectivity indices for S. mansoni lifecycle stages were cal-
culated from HepG2 CC50 values.
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